Project Grant RF1NS134638
Award Date
8/6/24
Completion Date
7/31/27
Dollars Obligated
$2.1M
Funding Federal Agency
National Institute on Aging
Awarding Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $655,638 Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to the University of Denver. The grant, which runs from September 2024 to February 2027, will support research to develop synthetic protein mimetics as potential therapeutics for Lewy Body Dementia (LBD). The project aims to optimize the pharmaceutical properties and efficacy of these synthetic protein mimetics in inhibiting alpha-synuclein aggregation and...
This $1,707,089 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports a research project led by Northwestern University. The project aims to synergistically enhance endoplasmic reticulum (ER) proteostasis, protein trafficking, and lysosomal activity as potential treatments for dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD). The researchers will use patient-derived induced pluripotent stem cell neuron models and mouse...
This three-year, $4.766 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, aims to clarify the neuropathological, molecular, and genetic differences between Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) through the Aging Research grant program (CFDA 93.866). The J. David Gladstone Institutes will use digital pathology, artificial intelligence, single-nuclei RNA sequencing, and spatial transcriptomics on...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $223,750 to Brigham & Women's Hospital Inc. to conduct research on distinguishing normal and abnormal forms of the protein alpha-synuclein (α-synuclein) and their impact on synaptic transmission. The research aims to elucidate the differences in the biological properties of normal and pathological phosphorylation of α-synuclein at serine 129 (pS129) in order to refine pS129 as a marker...
This federal Project Grant award of $7,704,350.00 was provided by the National Institute on Aging (CFDA 93.866 - Aging Research) to The Trustees of the University of Pennsylvania to fund a 5-year research center to investigate "Mechanisms Underlying Heterogeneity of Cognitive Outcomes in Synucleinopathy." The research center will conduct four synergistic projects to understand why the same alpha-synuclein pathology can lead to dramatically different cognitive trajectories in patients...
This federal Project Grant award, funded by the National Institute on Aging under CFDA program 93.866 Aging Research, supports research into the relationship between alpha-synucleinopathies (such as Lewy body dementia and Parkinson's disease) and T cell immunity in Alzheimer's disease and related dementias (ADRD). The $834,685 award aims to investigate the progression of alpha-synuclein pathology from the gut to the brain, emphasizing the role of the gut-brain axis, as well as explore the...
This $2,253,665 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the pathomechanisms of apolipoprotein E4 (APOE4), a major genetic risk factor for Lewy body dementia (LBD), and its influence on alpha-synuclein pathology. The primary research objectives are to: 1) conduct multi-omics profiling of human LBD brains to uncover lipid and endosomal-lysosomal dysfunction associated with APOE4, 2) use astrocyte-specific APOE3 or APOE4...
The National Institute on Aging (NIA) awarded a $717,491 Project Grant under its Aging Research program (CFDA 93.866) to New York University (NYU) School of Medicine to develop single domain antibodies (sdAbs) that can detect and clear alpha-synuclein (αSyn) in animal models of synucleinopathies. The project aims to evaluate the in vivo imaging potential, clearance mechanisms, and therapeutic efficacy of these sdAbs targeting αSyn, a key protein involved in neurodegenerative diseases like Lewy...
This $2,280,379 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to develop novel nanobody-based agents that can target intracellular and extracellular alpha-synuclein aggregates. The goal is to block the prion-like propagation of alpha-synuclein pathology, which is associated with Lewy body dementias including...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) totaling $1,641,495 will fund research at the University of Florida to investigate the molecular mechanisms by which mutations in the GBA1 gene influence the development of Lewy Body Dementia (LBD). The project will use induced pluripotent stem cell-derived neurons, both wildtype and with pathogenic GBA1 mutations, to examine how GBA1 impacts the regulation, trafficking, and maturation of key lysosomal...